Villepinte (France), November 21st, 2018 (8:00 CET) – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, today announced the worldwide launch of its new version of Contrast&Care®, a digital contrast media injection management solution for medical imaging centers, available in 14 languages.
Contrast&Care® 2.0 is a good demonstration of Guerbet’s commitment to strengthening its digital strategy, with the aim of improving the productivity of healthcare professionals and patient safety.
Offering “smart connectivity” and a new “smart reader” feature, version 2.0 connects with all CT, Cath Lab and MRI injectors in the current Guerbet range (OptiOne®, OptiVantage®, OptiStar® Elite, Illumena® Neo, FlowSens®) and allows users to scan and read data on mobile devices in addition to computers. These new functionalities have been added in response to requests from radiology professionals.
Contrast&Care® 2.0 will also benefit from a cloud support service approved for hosting healthcare data, in order to meet customers’ needs more rapidly and safely (installation, updates and maintenance).
Contrast&Care® is an integrated IT solution launched in November 2017 that groups together all data relating to examinations involving injections (contrast agent, injection protocol, patient data, etc.) and interfaces with the information systems used in radiology, including the RIS (Radiology Information System), the PACS (Picture Archiving and Communication System) and EMR (Electronic Medical Records). This solution improves efficiency and traceability and simplifies decision-making processes at imaging centers.
The information generated by injectors is sent automatically to Contrast&Care® following each examination.
Users can view the history of a patient’s data, the examinations involving injections and the doses of contrast media administered. Contrast&Care® also offers the optional ability to review protocols, create libraries of protocols and visualize statistics and trends on injection activity and use of contrast agents.
“We are delighted to be able to present this version 2.0 of Contrast&Care® as a demonstration of our commitment to further improve mobility, safety and productivity, in order to make it easier for healthcare professionals to take decisions. It is in line with our 5-year GEAR 2023 strategic plan aimed at shaping the future of medical imaging,” said David Hale, Chief Commercial Officer, Diagnostic Imaging.
The global commercial launch of Contrast&Care® 2.0 will begin during RSNA congress where Guerbet specialists will give interactive demonstrations.